Identification and regional distribution in rat brain of radiometabolites of the dopamine transporter PET radioligand [11C]PE2I

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 34, Issue 5, 2007, Pages 667-678

  Shetty, H Umesha ^a   Zoghbi, Sami S ^a   Liow, Jeih San ^a   Ichise, Masanori ^a   Hong, Jinsoo ^a   Musachio, John L ^a   Halldin, Christer ^b   Seidel, Jurgen ^c   Innis, Robert B ^a   Pike, Victor W ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

11C PE2I; Brain; Dopamine transporter; Metabolites; PET

Indexed keywords

DOPAMINE TRANSPORTER; DRUG METABOLITE; N (3 IODOPROP 2 ENYL) 2BETA CARBOMETHOXY 3BETA (4 METHYLPHENYL)NORTROPANE C 11; RADIOLIGAND; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BRAIN HOMOGENATE; BRAIN REGION; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RADIOCHROMATOGRAPHY; RADIOISOTOPE DISTRIBUTION; RAT;

ANIMALS; BRAIN; CHROMATOGRAPHY, LIQUID; MALE; MASS SPECTROMETRY; MODELS, CHEMICAL; MODELS, THEORETICAL; NORTROPANES; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RATS; RATS, SPRAGUE-DAWLEY; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 34247596015     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-006-0277-1     Document Type: Article

References (44)

1. 18F]CFT. Ann Neurol 2000;47:804-8.
2. 123I]β-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995;38:589-98.
3. Innis RB, Seibyl JP, Scanley BE, Laruelle M, Abi-Dargham A, Wallace E, et al. Single photon emission computed tomographic imaging demonstrates loss of striatal dopamine transporters in Parkinson disease. Proc Natl Acad Sci U S A 1993;90:11965-9.
4. Meyer JH, Krüger S, Wilson AA, Christensen BK, Goulding VS, Schaffer A, et al. Lower dopamine transporter binding potential in striatum during depression. NeuroReport 2001;12:4121-5.
5. Laakso A, Bergman J, Haaparanta M, Vilkman H, Solin O, Syvälahti E, et al. Decreased striatal dopamine transporter binding in vivo in chronic schizophrenia. Schizophr Res 2001;52:115-20.
6. 123I]beta-CIT SPECT imaging of striatal dopamine transporter binding in Tourette's disorder. Am J Psychiatry 1995;152:1359-61.
7. Emond P, Garreau L, Chalon S, Boazi M, Caillet M, Bricard J, et al. Synthesis and ligand binding of nortropane derivatives: N-substituted 2β-crabomethoxy-3β-(4′-iodophenyl)nortropane and N-(3-iodoprop-(2E)-enyl)-2β-carbomethoxy-3β-(3′, 4′-disubstituted phenyl)nortropane. New high-affinity and selective compounds for the dopamine transporter. J Med Chem 1997;40:1366-72.
8. Guilloteau D, Emond P, Baulieu J-L, Garreau L, Frangin Y, Pourcelot L, et al. Exploration of the dopamine transporter: in vitro and in vivo characterization of a high-affinity and high-specificity iodinated tropane derivative (E)-N-(3-iodoprop-2-enyl)-2β-carbomethoxy-3β- (4′-methylphenyl)nortropane (PE2I). Nucl Med Biol 1998;25:331-7.
9. Goodman MM, Keil R, Shoup TM, Eshima D, Eshima L, Kilts C, et al. Fluorine-18-FPCT: a PET radiotracer for imaging dopamine transporters. J Nucl Med 1997;38:119-26.
10. 18F]-labeled FECNT: a selective radioligand for PET imaging of brain dopamine transporters. Nucl Med Biol 2000;27:1-12.
11. Goodman MM, Kung M-P, Kabalka GW, Kung HF, Switzer R. Synthesis and characterization of radioiodinated N-(3-iodopropen-1-yl)-2β- carbomethoxy-3β-(4-chlorophenyl)tropanes: potential dopamine reuptake site imaging agents. J Med Chem 1994;37:1535-42.
12. Xing D, Chen P, Keil R, Kilts CD, Shi B, Camp VM, et al. Synthesis, biodistribution, and primate imaging of fluorine-18 labeled 2β-carbo- 1′-fluoro-2-propoxy-3β-(4-chlorophenyl)tropanes. Ligands for the imaging of dopamine transporters by positron emission tomography. J Med Chem 2000;43:639-48.
13. Neumeyer JL, Wang S, Gao Y, Milius RA, Kula NS, Campbell A, et al. N-ω-Fluoroalkyl analogs of (1R)-2β-carbomethoxy- 3β-(4-iodophenyl)tropane (β-CIT): radiotracers for positron emission tomography and single photon emission computed tomography imaging of dopamine transporters. J Med Chem 1994;37:1558-61.
14. 18F-FECNT. J Nucl Med 2003;44:855-61.
15. 18F]FECNT in naive and Parkinsonian rats following embryonic stem cell transplantation [abstract]. NeuroImage 2004;22:T27-T28.
16. 18F-2β- carbomethoxy-3β-(4-chlorophenyl)-8-(2-fluoroethyl)nortropane: a polar radiometabolite confounds brain radioligand measurements. J Nucl Med 2006;47:520-7.
17. Kuikka JK, Baulieu JL, Hiltunen J, Halldin C, Bergström K, Farde L, et al. Pharmacokinetics and dosimetry of iodine-123 labelled PE2I in humans, a radioligand for dopamine transporter imaging. Eur J Nucl Med 1998;25:531-4.
18. 11C]PE2I: a highly selective radioligand for PET examination of the dopamine transporter in monkey and human brain. Eur J Nucl Med Mol Imaging 2003;30:1220-30.
19. 11C]PE2I binding to the dopamine transporter in the human brain: a PET study. Eur J Nucl Med Mol Imaging 2006;33:657-68.
20. Jucaite A, Fernell E, Halldin C, Forssberg H, Farde L. Reduced midbrain dopamine transporter binding in male adolescents with attention-deficit/ hyperactivity disorder: association between striatal dopamine markers and motor hyperactivity. Biol Psychiatry 2005;57:229-38.
21. 11C]PE2I shows active and inactive radioactive metabolites in rat brain [abstract]. J Label Compds Radiopharm 2005;48 Suppl 1:S98.
22. Hawkins DR, editor. Biotransformations: a survey of the biotransformations of drugs and chemicals in animals. Cambridge: The Royal Society of Chemistry; 1992.
23. Jenner P, Testa B, editors. Concepts in drug metabolism. New York: Marcel Dekker, Inc.; 1980.
24. Woolf TF, editor. Handbook of drug metabolism. New York: Marcel Dekker, Inc.; 1999.
25. Guengerich FP. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol 2001;14:611-50.
26. Clark JD, Baldwin RL, Bayne KA, Brown MJ, Gebhart GF, Gonder JC, et al. Guide for the care and use of laboratory animals. Washington, DC: National Academy Press; 1996.
27. Seidel J, Vaquero JJ, Green MV. Resolution uniformity and sensitivity of the NIH ATLAS small animal PET scanner: comparison to simulated LSO scanners without depth-of-interaction capability. IEEE Trans Nucl Sci 2003;50:1347-50.
28. Johnson CA, Seidel J, Vaquero JJ, Pascau J, Desco M, Green MV. Exact positioning for OSEM reconstructions on the ATLAS depth-of-interaction small animal scanner [abstract]. Mol Imaging Biol 2002;4:S22.
29. Liow JS, Johnson CA, Toyama H, Green MV, Innis RB. A single slice rebinning/2D exact positioning OSEM reconstruction for the NIH ATLAS small animal PET scanner [abstract]. J Nucl Med 2003;44 Suppl:P163.
30. George P, Watson C. The rat brain in stereotaxic coordinates. 4th ed. San Diego: Academic Press; 1998.
31. McLafferty FW, Tureček F. Interpretation of mass spectra. 4th ed. Mill Valley: University Science Books; 1993.
32. n fragmentation in an electrospray ion trap. J Mass Spectrom 2003;38:793-808.
33. Thomas RC, Ikeda GJ. The metabolic fate of tolbutamide in man and in the rat. J Med Chem 1966;9:507-10.
34. Shetty HU, Nelson WL. Chemical aspects of metoprolol metabolism. Asymmetric synthesis and absolute configuration of the 3-[4-(l-hydroxy-2- methoxyethyl)phenoxy]-l-(isopropylamino)-2-propanols, the diastereomeric benzylic hydroxylation metabolites. J Med Chem 1988;31:55-9.
35. Andersson SHG, Lindgren A, Postlind H. Biotransformation of tolterodine, a new muscarinic receptor antagonist, in mice, rats and dogs. Drug Metab Disp 1998;26:528-35.
36. Hanioka H, Hamamura M, Kakino K, Ogata H, Jinno H, Takahashi A, et al. Dog liver microsomal P450 enzyme-mediated toluene biotransformation. Xenobiotica 1995;25:1207-17.
37. 14C]toluene by human and rat liver microsomal fractions and liver slices. Drug Metab Disp 1990;18:929-36.
38. Wagner FW, Burger AR, Vallee BL. Kinetic properties of human liver alcohol dehydrogenase: oxidation of alcohols by class I isoenzymes. Biochemistry 1983;22:1857-63.
39. m normal liver isozymes. J Biol Chem 1984;259:11986-90.
40. Rapoport SI, Ohno K, Pettigrew KD. Drug entry into the brain. Brain Res 1979;172:354-9.
41. Pardridge WM. CNS drug design based on principles of blood-brain barrier transport. J Neurochem 1998;70:1781-92.
42. Anandatheerthavarada HK, Boyd MR, Ravindranath V. Characterization of a phenobarbital-inducible cytochrome P-450, NADPH-cytochrome P-450 reductase and reconstituted cytochrome P-450 mono-oxygenase system from rat brain: evidence for constitutive presence in rat and human brain. Biochem J 1992;288:483-8.
43. Galter D, Carmine A, Buervenich S, Duester G, Olson L. Distribution of class I, III and IV alcohol dehydrogenase mRNAs in the adult rat, mouse and human brain. Eur J Biochem 2003;270:1316-26.
44. Erwin VG, Deitrich RA. Brain aldehyde dehydrogenase: localization, purification, and properties. J Biol Chem 1966;241:3533-9.